Oral Small Molecule Therapeutics
•254 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (254)
| Company | Market Cap | Price |
|---|---|---|
|
LLY
Eli Lilly and Company
Oral small molecule therapeutics like Orforglipron are a major asset.
|
$982.80B |
$1038.79
+0.56%
|
|
JNJ
Johnson & Johnson
Icotrokinra is an oral small-molecule therapeutic; CAPLYTA is also an oral small molecule.
|
$526.61B |
$218.68
-0.41%
|
|
ABBV
AbbVie Inc.
Rinvoq is an oral small-molecule therapeutic; AbbVie’s portfolio includes multiple oral small-molecule medicines.
|
$378.66B |
$214.31
-0.33%
|
|
AZN
AstraZeneca PLC
AZN's growing portfolio of oral small molecule therapeutics (e.g., Baxdrostat, AZD0780) represents a major growth vector.
|
$292.61B |
$94.41
+0.44%
|
|
MRK
Merck & Co., Inc.
Januvia/Janumet and other oral small-molecule programs position Merck in the oral therapeutics space.
|
$271.83B |
$108.84
-1.92%
|
|
PFE
Pfizer Inc.
Pfizer advances oral small molecule therapeutics, including internal programs and marketed oral medicines.
|
$145.83B |
$25.67
-0.85%
|
|
VRTX
Vertex Pharmaceuticals Incorporated
Vertex's CFTR modulators are oral small-molecule therapeutics, constituting a core product category.
|
$113.16B |
$441.61
+0.61%
|
|
BMY
Bristol-Myers Squibb Company
Milvexian and Iberdomide are oral small-molecule therapeutics, a major product category.
|
$112.48B |
$55.27
-2.38%
|
|
ZTS
Zoetis Inc.
Apoquel is an oral small-molecule therapeutic (JAK inhibitor) for dermatology, placing Zoetis in the Oral Small Molecule Therapeutics category.
|
$55.24B |
$124.63
-0.52%
|
|
TAK
Takeda Pharmaceutical Company Limited
Orexin agonists (orexin-based) and TYK2 inhibitors are predominantly oral small-molecule therapeutics.
|
$50.48B |
$16.16
-1.04%
|
|
ONC
BeOne Medicines Ltd.
BRUKINSA and pipeline assets are orally administered small-molecule therapeutics.
|
$37.25B |
$337.87
-0.12%
|
|
INSM
Insmed Incorporated
Brensocatib is an oral small molecule therapeutic targeting DPP1, a core part of Insmed's pipeline.
|
$34.12B |
$161.53
+1.42%
|
|
RVMD
Revolution Medicines, Inc.
Pipeline consists of small-molecule inhibitors targeting active RAS; aligns with oral small molecule therapeutics.
|
$22.48B |
$120.31
-2.40%
|
|
UTHR
United Therapeutics Corporation
Ralinepag is described as a once-daily oral prostacyclin receptor agonist, a small-molecule therapeutic under the company's late-stage pipeline.
|
$21.03B |
$464.94
-1.49%
|
|
INCY
Incyte Corporation
Incyte's pipeline includes multiple oral small-molecule agents (CDK2 inhibitor, BET inhibitor, KRAS G12D inhibitor, povorcitinib, etc.).
|
$20.74B |
$106.17
+0.88%
|
|
ROIV
Roivant Sciences Ltd.
Brepocitinib is an oral small molecule TYK2/JAK1 inhibitor, placing Roivant in the Oral Small Molecule Therapeutics space.
|
$15.80B |
$23.11
-0.79%
|
|
VTRS
Viatris Inc.
Viatris is developing and commercializing oral small-molecule therapeutics (e.g., meloxicam formulation, selatogrel, cenerimod).
|
$14.99B |
$12.86
+0.12%
|
|
BBIO
BridgeBio Pharma, Inc.
Attruby (acoramidis) and other BridgeBio pipeline assets are oral small-molecule therapeutics, covering multiple rare genetic diseases.
|
$14.58B |
$76.26
|
|
NBIX
Neurocrine Biosciences, Inc.
INGREZZA, CRENESSITY, and osavampator are described as oral small-molecule therapeutics advancing in neurology/psychiatry.
|
$13.13B |
$132.38
-0.73%
|
|
EXEL
Exelixis, Inc.
Zanzalintinib and cabozantinib are oral small-molecule therapeutics (TKIs) in Exelixis' portfolio.
|
$11.83B |
$43.99
-3.19%
|
|
MDGL
Madrigal Pharmaceuticals, Inc.
Rezdiffra is an oral, small-molecule therapeutic (THR-β agonist) approved for MASH, directly matching the 'Oral Small Molecule Therapeutics' category.
|
$11.18B |
$501.63
+1.16%
|
|
VRNA
Verona Pharma plc
Verona's Ohtuvayre (ensifentrine) is a small-molecule therapeutic used for COPD management.
|
$9.10B |
$106.91
|
|
AXSM
Axsome Therapeutics, Inc.
Axsome's revenue drivers Auvelity and Sunosi and pipeline products are oral small-molecule therapeutics.
|
$8.85B |
$177.27
+1.80%
|
|
BPMC
Blueprint Medicines Corporation
AYVAKIT and pipeline small-molecule candidates are oral therapeutics, fitting Oral Small Molecule Therapeutics.
|
$8.27B |
$129.46
|
|
NUVL
Nuvalent, Inc.
Lead programs are orally administered small-molecule inhibitors targeting ROS1/ALK in cancer, aligning with Oral Small Molecule Therapeutics.
|
$7.52B |
$104.26
-1.79%
|
|
CYTK
Cytokinetics, Incorporated
Aficamten is described as an oral, small-molecule therapeutic; the lead program supports 'Oral Small Molecule Therapeutics'.
|
$7.49B |
$62.58
-1.36%
|
|
ABVX
Abivax S.A.
Obefazimod is an oral small-molecule therapeutic targeting inflammatory pathways in IBD.
|
$7.43B |
$116.92
+0.11%
|
|
RYTM
Rhythm Pharmaceuticals, Inc.
Bivamelagon is an oral small-molecule MC4R agonist in Phase 2, representing a major product category in Rhythm's pipeline.
|
$6.75B |
$101.67
-4.14%
|
|
PRAX
Praxis Precision Medicines, Inc.
Praxis's Cerebrum platform develops oral small-molecule CNS therapies (e.g., ulixacaltamide, Vormatrigine).
|
$6.68B |
$317.12
+6.51%
|
|
PTCT
PTC Therapeutics, Inc.
Sephience PKU and other PTC therapies are oral small-molecule drugs, a major product category for the company.
|
$5.76B |
$72.50
-4.14%
|
|
COGT
Cogent Biosciences, Inc.
Cogent's lead asset bezuclastinib and the described pipeline assets are primarily oral small-molecule tyrosine kinase inhibitors, i.e., Oral Small Molecule Therapeutics.
|
$5.44B |
$38.92
-0.84%
|
|
CRNX
Crinetics Pharmaceuticals, Inc.
Crinetics develops oral, nonpeptide small-molecule therapeutics (lead platform) targeting GPCRs and related pipelines.
|
$5.27B |
$55.97
-0.82%
|
|
ALKS
Alkermes plc
Direct product category encompassing Alkermes' oral small-molecule therapeutics, including LYBALVI.
|
$5.22B |
$31.62
+1.30%
|
|
GPCR
Structure Therapeutics Inc.
Company focuses on developing oral small-molecule GPCR-targeted therapeutics, including lead GLP-1R agonist and other oral GPCR modulators.
|
$5.10B |
$88.70
+4.33%
|
|
KYMR
Kymera Therapeutics, Inc.
Kymera's core offering is oral small molecule therapeutics designed to degrade disease-causing proteins (STAT6, IRAK4, IRF5) in immunology indications.
|
$4.97B |
$69.47
-2.32%
|
|
BLTE
Belite Bio, Inc
Tinlarebant is an oral small molecule therapeutic; pipeline also includes LBS-009 with oral delivery.
|
$4.94B |
$155.06
+3.64%
|
|
MIRM
Mirum Pharmaceuticals, Inc.
LIVMARLI and volixibat are oral small molecule therapeutics for cholestatic diseases.
|
$4.57B |
$91.08
-1.34%
|
|
FOLD
Amicus Therapeutics, Inc.
Galafold is an oral pharmacological chaperone and Pombiliti + Opfolda include an oral stabilizer; both are delivered as oral small molecule drugs, making Oral Small Molecule Therapeutics a core product category.
|
$4.42B |
$14.32
+0.07%
|
|
ACAD
ACADIA Pharmaceuticals Inc.
ACADIA's portfolio includes Pimavanserin (NUPLAZID) and pipeline candidates that are small-molecule therapeutics, with additional small-molecule programs (e.g., ACP-204, ACP-711).
|
$4.38B |
$25.98
-2.05%
|
|
INDV
Indivior PLC
INDV-2000 is an oral small-molecule Orexin-1 receptor antagonist, aligning with the Oral Small Molecule Therapeutics category.
|
$4.06B |
$32.53
-1.06%
|
|
CORT
Corcept Therapeutics Incorporated
Corcept develops and commercializes oral small-molecule cortisol modulators (Korlym, relacorilant) for hypercortisolism and oncology, fitting 'Oral Small Molecule Therapeutics'.
|
$3.66B |
$34.76
-1.78%
|
|
NAMS
NewAmsterdam Pharma Company N.V.
Lead asset obicetrapib is an oral, small-molecule therapeutic, aligning with the 'Oral Small Molecule Therapeutics' category.
|
$3.56B |
$31.64
-0.58%
|
|
SWTX
SpringWorks Therapeutics, Inc.
Core drug modalities are oral small-molecule therapeutics (e.g., nirogacestat, mirdametinib).
|
$3.52B |
$46.99
|
|
TERN
Terns Pharmaceuticals, Inc.
The company is advancing oral small-molecule therapeutics (TERN-701 and TERN-601) for cancer and obesity, aligning with the 'Oral Small Molecule Therapeutics' investable theme.
|
$3.20B |
$36.63
-0.95%
|
|
IDYA
IDEAYA Biosciences, Inc.
Pursues oral small-molecule therapeutics across multiple targets in its pipeline.
|
$3.14B |
$35.83
-0.64%
|
|
XENE
Xenon Pharmaceuticals Inc.
Azetukalner is a small-molecule therapeutic administered orally, placing the program under Oral Small Molecule Therapeutics.
|
$3.08B |
$40.02
-1.77%
|
|
TARS
Tarsus Pharmaceuticals, Inc.
TP-05 is an oral systemic lotilaner candidate (Lyme disease prophylaxis), representing a major pipeline in an oral small-molecule therapeutics category.
|
$3.00B |
$71.15
-3.39%
|
|
CNTA
Centessa Pharmaceuticals plc
ORX750 is an orally administered, high-potency orexin receptor 2 (OX2R) agonist, fitting the 'Oral Small Molecule Therapeutics' category.
|
$2.98B |
$22.20
-0.89%
|
|
EWTX
Edgewise Therapeutics, Inc.
Edgewise's lead programs sevasemten and EDG-7500 are orally administered small-molecule therapeutics, i.e., an oral small molecule therapeutics platform.
|
$2.89B |
$27.41
+3.06%
|
|
SUPN
Supernus Pharmaceuticals, Inc.
Qelbree and ONAPGO are oral small-molecule therapeutics across ADHD and Parkinson's disease indications, and SPN-817/SPN-820/SPN-443 are oral small molecules in development.
|
$2.80B |
$50.04
-0.44%
|
|
CPRX
Catalyst Pharmaceuticals, Inc.
CPRX directly develops and sells oral small molecule therapeutics (FIRDAPSE, AGAMREE, FYCOMPA).
|
$2.78B |
$22.71
-1.09%
|
|
BHC
Bausch Health Companies Inc.
Xifaxan and the RED-C program are oral small-molecule therapeutics within the Salix hepatology portfolio.
|
$2.58B |
$6.99
-3.79%
|
|
TVTX
Travere Therapeutics, Inc.
Lead product FILSPARI (sparsentan) is an oral small molecule therapeutic for IgA nephropathy, representing the core commercial and product-focused program.
|
$2.48B |
$27.87
-1.87%
|
|
ALMS
Alumis Inc. Common Stock
Alumis is developing oral TYK2 inhibitors (ESK-001 and A-005), a major product category of oral small molecule therapeutics.
|
$2.48B |
$23.86
-1.30%
|
|
IRON
Disc Medicine, Inc.
Lead assets and pipeline candidates are small molecules (e.g., bitopertin), indicating a primary focus on oral small-molecule therapeutics.
|
$2.47B |
$71.00
-0.06%
|
|
AAPG
ASCENTAGE PHARMA GROUP INTERNATIONAL
The company’s assets are orally administered small-molecule therapeutics (BCR-ABL inhibitor, Bcl-2 inhibitor, MDM2-p53 inhibitor).
|
$2.36B |
$27.08
-0.81%
|
|
RCUS
Arcus Biosciences, Inc.
Casdatifan and other assets are oral small molecule therapeutics, aligning with the Oral Small Molecule Therapeutics tag.
|
$2.32B |
$21.80
+0.02%
|
|
OGN
Organon & Co.
Rayvow is an oral small-molecule migraine therapeutic, a direct product category.
|
$2.28B |
$8.75
+0.57%
|
|
SLNO
Soleno Therapeutics, Inc.
Core product category: Soleno's VYKAT XR is an oral small molecule therapeutic (diazoxide choline extended-release) targeting hyperphagia in Prader-Willi Syndrome.
|
$2.26B |
$42.52
+1.35%
|
|
GLPG
Galapagos N.V.
GLPG3667 TYK2 inhibitor represents an oral small-molecule therapeutic program.
|
$2.21B |
$33.52
-1.50%
|
|
MLYS
Mineralys Therapeutics, Inc.
Lorundrostat is an orally administered small-molecule therapeutic targeting aldosterone synthesis for hypertension, classifiable as an Oral Small Molecule Therapeutic.
|
$2.17B |
$32.75
+4.37%
|
|
AVDL
Avadel Pharmaceuticals plc
LUMRYZ is an oral small molecule therapeutic (sodium oxybate) used to treat narcolepsy; Avadel's core product.
|
$2.09B |
$21.50
+0.07%
|
|
HRMY
Harmony Biosciences Holdings, Inc.
EPX-100/EPX-200 are small-molecule therapeutics (oral/liquid lorcaserin) in Phase 3, supporting the Orals Small Molecule Therapeutics category.
|
$2.08B |
$36.18
-0.63%
|
|
ZLAB
Zai Lab Limited
Major portfolio of oral small molecule therapeutics (ZEJULA, NUZYRA, QINLOCK, AUGTYRO, XACDURO, etc.).
|
$2.04B |
$18.57
-1.33%
|
|
NUVB
Nuvation Bio Inc.
IBTROZI and pipeline agents are orally administered small molecule therapeutics, aligning with Oral Small Molecule Therapeutics.
|
$2.00B |
$5.84
-4.80%
|
|
AUPH
Aurinia Pharmaceuticals Inc.
LUPKYNIS is an oral small-molecule therapeutic, and Aurinia's AUR200 program reflects a focus on oral small-molecule therapeutics in its pipeline.
|
$1.95B |
$14.86
-0.10%
|
|
IMNM
Immunome, Inc.
Varegacestat is an oral small-molecule therapeutic (gamma secretase inhibitor).
|
$1.95B |
$22.43
-1.86%
|
|
OLMA
Olema Pharmaceuticals, Inc.
Palazestrant and OP-3136 are oral small-molecule therapeutics developed for cancer, fitting the 'Oral Small Molecule Therapeutics' category.
|
$1.86B |
$27.14
-7.04%
|
|
ANIP
ANI Pharmaceuticals, Inc.
Prucalopride Tablets with 180-day CGT exclusivity expand ANI's oral small molecule therapeutic offerings within Generics.
|
$1.84B |
$84.85
-0.52%
|
|
MAZE
Maze Therapeutics, Inc.
Maze develops small molecule therapeutics, including MZE829 and MZE782, which are oral small molecule treatments for renal/cardiovascular/metabolic diseases.
|
$1.79B |
$40.85
+2.61%
|
|
SNDX
Syndax Pharmaceuticals, Inc.
Revuforj is an oral small-molecule therapy (menin inhibitor), fitting Oral Small Molecule Therapeutics.
|
$1.77B |
$20.50
-0.82%
|
|
SION
Sionna Therapeutics, Inc.
Lead candidates are oral small-molecule therapeutics (SION-719, SION-451) in clinical development.
|
$1.73B |
$39.12
+0.71%
|
|
ARDX
Ardelyx, Inc.
Ardelyx's core offerings are oral, small-molecule therapeutics (IBSRELA and XPHOZAH) based on tenapanor.
|
$1.63B |
$6.75
-4.12%
|
|
ELVN
Enliven Therapeutics, Inc.
Lead products are oral small-molecule therapeutics (kinase inhibitors) used in oncology.
|
$1.58B |
$26.71
+6.14%
|
|
AGIO
Agios Pharmaceuticals, Inc.
Lead assets PYRUKYND (mitapivat) and tebapivat are oral small-molecule PK activators targeting red blood cell metabolism in rare hematologic diseases, representing Agios's core product strategy.
|
$1.58B |
$27.20
-2.18%
|
|
TYRA
Tyra Biosciences, Inc.
TYRA-300 is an oral FGFR3-selective small-molecule inhibitor; TYRA develops oral small-molecule therapeutics.
|
$1.53B |
$28.77
-0.86%
|
|
NRIX
Nurix Therapeutics, Inc.
Lead candidate NX-5948 is an orally bioavailable degrader, confirming the company’s core business in Oral Small Molecule Therapeutics.
|
$1.47B |
$19.21
+1.88%
|
|
GLUE
Monte Rosa Therapeutics, Inc.
GLUE develops oral small-molecule molecular glue degraders (MGDs) as its core therapeutic modality.
|
$1.46B |
$23.70
-1.58%
|
|
TNGX
Tango Therapeutics, Inc.
Lead programs are small-molecule inhibitors designed as oral therapeutics (TNG462, TNG456), fitting the Oral Small Molecule Therapeutics investable theme.
|
$1.45B |
$13.00
+11.21%
|
|
COLL
Collegium Pharmaceutical, Inc.
Jornay PM, Belbuca, Xtampza ER, and Nucynta are all oral small-molecule therapeutics, representing major product categories in Collegium's portfolio.
|
$1.44B |
$45.56
-2.86%
|
|
BCRX
BioCryst Pharmaceuticals, Inc.
ORLADEYO is BioCryst's flagship oral small-molecule therapy for hereditary angioedema, a core product.
|
$1.40B |
$6.66
-7.18%
|
|
BHVN
Biohaven Ltd.
Troriluzole and other neuroscience-focused assets are oral small-molecule therapeutics.
|
$1.39B |
$13.13
+10.15%
|
|
PHVS
Pharvaris N.V.
Pharvaris' lead program deucrictibant is an oral small-molecule therapeutic targeting Bradykinin B2 receptor for HAE/AAE, fitting the 'Oral Small Molecule Therapeutics' category.
|
$1.37B |
$25.10
-2.14%
|
|
TRVI
Trevi Therapeutics, Inc.
Trevi Therapeutics develops Haduvio, an oral small molecule therapeutic (nalbuphine ER) for chronic cough.
|
$1.28B |
$10.47
-2.65%
|
|
AMLX
Amylyx Pharmaceuticals, Inc.
AMX0035 is an oral fixed-dose combination therapy, aligning with the 'Oral Small Molecule Therapeutics' investable theme.
|
$1.28B |
$14.29
+5.73%
|
|
RLAY
Relay Therapeutics, Inc.
RLY-2608 is a small molecule therapeutic (PI3Kα inhibitor), representing an oral small molecule oncology drug category.
|
$1.27B |
$7.34
-3.74%
|
|
PHAR
Pharming Group N.V.
Joenja is an oral small-molecule therapeutic; KL1333 (Abliva) is a small-molecule asset for primary mitochondrial disease, both fitting the 'Oral Small Molecule Therapeutics' category.
|
$1.25B |
$18.39
+1.27%
|
|
INVA
Innoviva, Inc.
Zoliflodacin is an oral small-molecule therapeutic in Innoviva's pipeline, representing the IST focus on oral antibiotics.
|
$1.23B |
$19.43
-1.67%
|
|
XERS
Xeris Biopharma Holdings, Inc.
XP-8121 is a small-molecule hormone therapy in development (levothyroxine) representing a potential new oral/small-molecule category for hypothyroidism.
|
$1.21B |
$7.53
+1.62%
|
|
ORIC
ORIC Pharmaceuticals, Inc.
Lead assets are oral small-molecule therapeutics (PRC2/EED inhibitor ORIC-944; EGFR exon 20/HER2 exon 20 inhibitor ORIC-114); hence, the company is an oral small molecule therapeutics company.
|
$1.18B |
$12.12
+5.16%
|
|
SEPN
Septerna, Inc.
Septerna is focused on discovering and developing oral small molecule therapeutics targeting GPCRs (e.g., preclinical metabolic programs and GPCR targets under Novo Nordisk collaboration), which maps to the 'Oral Small Molecule Therapeutics' investable theme.
|
$1.16B |
$26.11
-4.66%
|
|
MNMD
Mind Medicine (MindMed) Inc.
MM120 employs an oral small-molecule therapeutic approach with an OdT/formulation, aligning with the Oral Small Molecule Therapeutics category.
|
$1.15B |
$15.02
+2072.72%
|
|
DAWN
Day One Biopharmaceuticals, Inc.
Day One Biopharmaceuticals markets and develops Oral Small Molecule Therapeutics (OJEMDA/tovorafenib) as a lead product.
|
$1.04B |
$10.13
-3.52%
|
|
ERAS
Erasca, Inc.
ERAS-0015, ERAS-4001, and naporafenib are small-molecule targeted therapies (RAF/KRAS inhibitors), fitting Oral Small Molecule Therapeutics.
|
$1.02B |
$3.58
+6.07%
|
|
TBPH
Theravance Biopharma, Inc.
Ampreloxetine is an oral small-molecule therapeutic in Phase 3 (CYPRESS) for symptomatic nOH in MSA, representing a core TBPH pipeline asset.
|
$1.01B |
$20.02
-0.47%
|
|
PHAT
Phathom Pharmaceuticals, Inc.
VOQUEZNA (vonoprazan) is an oral small-molecule therapeutic (P-CAB) with GERD and H. pylori indications, representing the company’s core product line.
|
$997.47M |
$14.05
-6.17%
|
|
VTYX
Ventyx Biosciences, Inc.
VTX assets are oral small molecule therapeutics for autoimmune/inflammatory diseases (NLRP3 inhibitors).
|
$990.48M |
$13.88
+0.14%
|
|
RAPP
Rapport Therapeutics, Inc. Common Stock
Rapport develops small molecule therapeutics (RAP-219 and discovery-stage nAChR modulators), fitting the oral small molecule therapeutics category.
|
$978.51M |
$26.81
-0.19%
|
|
OMER
Omeros Corporation
Pipeline includes oral small-molecule therapeutics in addition to biologics.
|
$958.91M |
$13.94
-1.10%
|
|
ABUS
Arbutus Biopharma Corporation
AB-101 is described as an oral small-molecule PD-L1 inhibitor, representing an oral small molecule therapeutics product line.
|
$948.91M |
$4.58
-7.58%
|
Showing page 1 of 3 (254 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
